HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Clinical trial NCT06125314 · COMPLETED

Trial details

NCT number: NCT06125314
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Breast Neoplasms Breast Cancer Breast Carcinoma Genes HER2

Start date: 2024-03-05
Primary completion: 2024-09-30
Enrollment: 517

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.